HepeX-C (XTL-002) is a monoclonal antibody (an artificially produced antibody, made in the lab by use of
an immortalized cell line that binds to one unique marker on a virus's surface) whose target is the HCV envelope
protein. It recognizes many different genotypes. In pre-clinical trials, HepeX-C decreased HCV load by greater than
90% in the HCV Trimera model. XTL Bio has begun phase II trials in HCV infected post-transplant patients as of October 2003,
with results expected near the end of the year. Phase I trials showed safety and effectivity.